Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisation

Primary objectives: prevention of growth of liver metastase during liver expansion
Primary endpoints: Total sum of liver metastases diameter for each patient measured by CT as baseline at start of cetuximab and evaluated by CT 6 weeks after portal embolisation. The follow-up CT will be evaluated for changes in the total sum of lesion diameters and expansion of the contralateral liver volume. occurence of new lesions will be registered.